4 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $23M | -$27M | 83.8% | -113.7% | -$1M | $9M | $178321 |
| 2024 | $37M | $12M | 88.2% | 41.4% | -$9M | $4M | $3M |
| 2023 | $31M | $11M | 86.6% | 37.7% | -$4M | $2M | — |
| 2022 | $35M | — | 79.9% | 38.8% | -$5M | — | — |
How the market has priced BDMD against its own fundamentals since 2024-10 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 3 years, Baird Medical Investment Holdings Ltd's revenue has declined 13.7% per year. These are computed facts, not advice.
As of FY2025, Baird Medical Investment Holdings Ltd reported $9M of total debt against $178321 of cash; operating income covered interest expense -34.8×.
In FY2025, gross margin was 83.8%, operating margin -113.7%, and net margin -121.0%.
As of Jun '26, Baird Medical Investment Holdings Ltd traded at a price-to-earnings ratio of about 3.0× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.